For your patients with ER+, HER2-, node negative or node positive breast cancer, EndoPredict provides three individualized results you can use when determining the treatments that are right for them.
For patients with ER+, HER2-, node negative or node positive breast cancer in early stages, EndoPredict is a next generation prognostic genomic test that predicts individual risk of early and late breast cancer recurrence across years 0-15. By knowing your patient’s individualized absolute chemotherapy benefit and predicted distant recurrence up to 15 years at the time of diagnosis, the EndoPredict test helps you make informed adjuvant treatment decisions for your breast cancer patients.
The EndoPredict report provides you and your patient with a clear, individualized risk of recurrence risk for years 0-10 based on their tumor’s specific biology and pathology. Your patient will also receive an individualized absolute chemotherapy benefit specific to her tumor. By knowing this information, you’ll know your patient’s risk of recurrence at 5-15 years and whether they might safely forego extended endocrine therapy.
At Myriad, we believe every patient should have access to the highest quality testing so you can deliver the best medical care possible. When you order EndoPredict for your patients, we will work with their insurance provider to help them get the appropriate coverage allowed by their plan and can also offer other options like our financial assistance program.
If your patient has questions about billing or coverage, please direct them to call Myriad at 800-469-7423 for more details.
Start individualizing treatment decisions for your breast cancer patients with EndoPredict.